In support of this hypothesis, it has been previously reported that the combined Menin and FLT3 inhibition exerts synergistic effect in MLL-r and NPM1-mut leukemias.27,32 We therefore examined if the FLT3 inhibitor gilteritinib also synergises with revumenib in interfering with the expansion of NUP98::NSD1 FLT3-ITD+ patient-derived AML cells. FLT3 inhibition was found to be highly efficient against these AML cells (IC50= 30 nM), while primary AML cells (RUNX1::ETO) without FLT3 mutation were unaffected (Figure 3H). This evidence concerns the gene MEN1 and acute myeloid leukemia.